Skip to Main Content

Paper Details

Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression: <i>the ASSURE study</i>.
Psychol Med
1
2023
ADHD, Attention deficit-hyperactivity disorder, Fluoxetine, MPH, MPHs, adolescent ADHD, attention-deficit/hyperactivity disorder, depression, depressive disorder, escitalopram, fluoxetine, methylphenidate, patients, respiratory tract infection, serotonin, serotonin reuptake, tic disorder
Author NameAffiliation
Joo Hun ParkAjou University Graduate School of Medicine
Eng Hooi TanUniversity of Oxford
Daniel Prieto-AlhambraUniversity of Oxford
Daniel Prieto-AlhambraErasmus University Medical Center
Daniel Prieto-AlhambraUniversity of Oxford
Daniel Prieto-AlhambraErasmus University Medical Center
Rae Woong ParkAjou University Graduate School of Medicine
Rae Woong ParkAjou University School of Medicine
Rae Woong ParkAjou University Graduate School of Medicine
Rae Woong ParkAjou University School of Medicine
  • 1 - 10

Datasets

Release 1.2